




Corrigendum

Corrigendum to “Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models” [Bioorg. Med. Chem. Lett. 21 (2011) 463]

Eugen F. Mesaros*, Jason P. Burke, Jonathan D. Parrish, Benjamin J. Dugan, Andrew V. Anzalone, Thelma S. Angeles, Mark S. Albom, Lisa D. Aimone, Matthew R. Quail, Weihua Wan, Lihui Lu, Zeqi Huang, Mark A. Ator, Bruce A. Ruggeri, Mangeng Cheng, Gregory R. Ott*, Bruce D. Dorsey

Worldwide Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, PA 19380, USA

Structure **3** in Figure 1 appeared incorrectly. The corrected structure appears here.



DOI of original article: [10.1016/j.bmcl.2010.10.115](https://doi.org/10.1016/j.bmcl.2010.10.115).

* Corresponding authors. Tel.: +1 610 738 6168; fax: +1 610 738 6643 (E.F.M.); tel.: +1 610 738 6861; fax: +1 610 738 6643 (G.R.O.).

E-mail addresses: emesaros@cephalon.com (E.F. Mesaros), gott@cephalon.com (G.R. Ott).